Dry Eye Disease Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) - Estimates DelveInsight | Alcon, Allysta, Aramis, Dreamhawk Vision, Invirsa, Kowa, Novaliq, Novaliq, Noveome, Seikagaku, Seinda, Serentrix, Taejoon

As per DelveInsight, the Dry Eye Disease Market is anticipated to evolve immensely in the coming years owing to the increasing prevalent population of Dry Eye Disease patients in the 7MM, along with the expected entry of emerging drugs.

DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Dry Eye Disease Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Dry Eye Disease therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Dry Eye Disease treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Dry Eye Disease: An Overview
Dry eye disease (DED), also known as dry eye syndrome (DES) or keratoconjunctivitis sicca (KCS), is a common condition when the eyes do not produce enough tears or the tears evaporate too quickly. As tears are essential to lubricate and nourish the eye, the condition leads to eyes drying out and becoming red, swollen, and irritated. Causes for Dry Eye Disease include decreased tear production, excessive tear evaporation, and abnormality in the production of mucus or lipids of the tear layer.

It is caused by a chronic lack of sufficient lubrication and moisture on the surface of the eye. Consequences of dry eyes range from subtle but constant eye irritation to significant inflammation and even scarring of the front surface of the eye. It can affect one or both eyes, and it can lead to inflammation.

Dry Eye Disease Market Key Facts
• According to a study conducted by Farrand et al. (2017), based on weighted estimates, 6.8% of the US adult population was projected to have been diagnosed with Dry Eye Disease. Prevalence increased with age (18-34 years: 2.7%; ≥75 years: 18.6%) and was higher among women (8.8%) than men (4.5%). After adjustment, there were no substantial differences in prevalence/risk of diagnosed Dry Eye Disease by race, education, or the US census region.
• According to Dana et al. (2019), the overall Dry Eye Disease prevalence was 5.28%, wherein the prevalence among females and males was about 7.78% and 2.96%, respectively, in the US. Besides, the prevalence increased with age from 0.20%, for ages 2-17 years, to 11.66% for individuals aged above 50.
• According to a study by Dalton et al. (2019), around 16 million Americans have been diagnosed with Dry Eye Disease, but the actual number of Americans suffering from dry eye symptoms is likely much higher. Some reports indicate that nearly half of all US adults experience dry eye signs and symptoms, and 33% of patients in eye care clinics present with complaints about dry eye.

Dry Eye Disease Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Dry Eye Disease therapies in the market. It also provides a detailed assessment of the Dry Eye Disease market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Dry Eye Disease drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Dry Eye Disease Market Will Grow by 2032:
https://www.delveinsight.com/report-store/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Dry Eye Disease Epidemiology
The epidemiology section covers detailed insights into the historical, and current Dry Eye Disease patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Dry Eye Disease Epidemiology Segmented as -
• Total Prevalent Cases of Dry Eye Disease in the 7MM (2019-2032)
• Total Diagnosed Prevalent Cases of Dry Eye Disease in the 7MM (2019-2032)
• Type-specific Diagnosed Prevalent Cases of Dry Eye Disease in the 7MM (2019-2032)
• Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease in the 7MM (2019-2032)
• Age-specific Diagnosed Prevalent Cases of Dry Eye Disease in the 7MM (2019-2032)
• Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease in the 7MM (2019-2032)
• Treated Cases of Dry Eye Disease in the 7MM (2019-2032)

Get Key Insights Into the Evolving Dry Eye Disease Epidemiology Trends @
https://www.delveinsight.com/report-store/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Dry Eye Disease Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dry Eye Disease market or expected to be launched during the study period. The analysis covers the market share by Dry Eye Disease drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Dry Eye Disease Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Dry Eye Disease Therapeutics Assessment
The disease management aims to relieve the discomfort and prevent damage to the cornea, at the front of the eye. Currently, the available treatment options for Dry Eye Disease depend on the severity of the condition. They may include medication, surgery, and others (eyelid therapy [warm compresses and eyelid hygiene, contact lenses, and moisture chamber spectacles]).

Treatment depends on the underlying cause. Artificial tears are the usual first-line treatment. Wrap-around glasses that fit close to the face may decrease tear evaporation. Stopping or changing certain medications may help. The medication cyclosporine or steroid eye drops may be used in some cases. Another option is lacrimal plugs that prevent tears from draining from the surface of the eye. DES occasionally makes wearing contact lenses impossible. Various therapies like MIEBO (perfluorohexyloctane ophthalmic solution), XIIDRA (lifitegrast ophthalmic solution), and TYRVAYA nasal spray, among others are approved for the treatment of the signs and symptoms of dry eye disease

Several major pharma and biotech companies are developing therapies for Dry Eye Disease. The dynamics of the Dry Eye Disease market are anticipated to experience a positive shift in the coming years owing to the expected launch of a barrage of emerging therapies like OTX-DED (Ocular Therapeutix), HL036 (tanfanercept) (HanAll Biopharma/Daewoong Pharmaceutical, PL9643 (Palatin Technologies) and many others during the forecast. Currently, Alcon is leading the therapeutics market with its Dry Eye Disease drug candidates in the most advanced stage of clinical development.

Leading Companies in the Dry Eye Disease Therapeutics Market Include
• Alcon
• Allysta Pharmaceuticals
• Aramis Biosciences
• BRIM Biotechnology
• Dreamhawk Vision Biotech, Inc.
• HanAll Biopharma
• Invirsa
• IVIEW Therapeutics
• Kowa Company
• Mc2 therapeutics
• Novaliq
• Novaliq GmbH
• Noveome
• Ocular Therapeutix
• Palatin Technologies
• Quorum Innovations
• Seikagaku Corporation
• Seinda Pharmaceutical
• Serentrix
• Taejoon Pharmaceutical
And Many Others

Emerging and Marketed Dry Eye Disease Therapies Covered in the Report Include
• AR-15512: Alcon
• HL036: HanAll Biopharma
• OTX-DED: Ocular Therapeutix
• SY-201: Seinda Pharmaceutical
• iVIEW 1001: IVIEW Therapeutics
And Many Others

Learn More About the Emerging Therapies and key Companies in the Dry Eye Disease Therapeutics Market:
https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Dry Eye Disease Competitive Intelligence Analysis
4. Dry Eye Disease Market Overview at a Glance
5. Dry Eye Disease Background and Overview
6. Dry Eye Disease Patient Journey
7. Dry Eye Disease Epidemiology and Patient Population
8. Dry Eye Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Dry Eye Disease Unmet Needs
10. Key Endpoints of Dry Eye Disease Treatment
11. Dry Eye Disease Marketed Products
12. Dry Eye Disease Emerging Therapies
13. Dry Eye Disease Seven Major Market Analysis
14. Attribute Analysis
15. Dry Eye Disease Market Outlook (7 major markets)
16. Dry Eye Disease Access and Reimbursement Overview
17. KOL Views on the Dry Eye Disease Market.
18. Dry Eye Disease Market Drivers
19. Dry Eye Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.